Investigating the utility of previously developed prediction scores in acute ischemic stroke patients in the stroke belt

Journal of Stroke and Cerebrovascular Diseases

Volumn 23, Issue 8, 2014, Pages 2001-2006

  Boehme, Amelia K ^a,b   Rawal, Pawan V ^a   Lyerly, Michael J ^a,c   Albright, Karen C ^b,d,e   Bavarsad Shahripour, Reza ^a   Palazzo, Paola ^a   Kapoor, Niren ^a   Alvi, Mohammad ^a   Houston, J Thomas ^a   Harrigan, Mark R ^f   Cava, Luis ^g   Sisson, April ^a   Alexandrov, Anne W ^h   Alexandrov, Andrei V ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

^d Center for Outcomes and Effectiveness Research   (United States)

^e Center of Excellence in Comparative Effectiveness Research for Eliminating Disparities (CERED) Minority Health and Health Disparities Research Center (MHRC)   (United States)

^f University of Alabama at Birmingham   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

epidemiology; outcome; Stroke; stroke recovery

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RANKIN SCALE; RETROSPECTIVE STUDY; SCORING SYSTEM; STROKE PATIENT; TREATMENT OUTCOME; ACUTE DISEASE; ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DECISION SUPPORT SYSTEM; EMBOLECTOMY; FIBRINOLYTIC THERAPY; GLUCOSE BLOOD LEVEL; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; RADIOGRAPHY; RISK FACTOR; STROKE;

ACUTE DISEASE; ADULT; AGED; BLOOD GLUCOSE; BRAIN ISCHEMIA; DECISION SUPPORT TECHNIQUES; EMBOLECTOMY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84908131333     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2014.02.003     Document Type: Article

References (22)

1. A. Towfighi, and J.L. Saver Stroke declines from third to fourth leading cause of death in the United States: historical perspective and challenges ahead Stroke 42 2011 2351 2355
2. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group N Engl J Med 333 1995 1581 1587
3. W. Hacke, M. Kaste, and E. Bluhmki Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke N Engl J Med 359 2008 1317 1329
4. M.J. Reeves, S. Arora, and J.P. Broderick Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry Stroke 36 2005 1232 1240
5. J.C. Grotta, W.S. Burgin, and A. El-Mitwalli Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000 Arch Neurol 58 2001 2009 2013
6. D. Kleindorfer, Y. Xu, and C.J. Moomaw US geographic distribution of rt-PA utilization by hospital for acute ischemic stroke Stroke 40 2009 3580 3584
7. O. Adeoye, R. Hornung, and P. Khatri Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years Stroke 42 2011 1952 1955
8. D.L. Brown, W.G. Barsan, and L.D. Lisabeth Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke Ann Emerg Med 46 2005 56 60
9. K.Z. Bambauer, S.C. Johnston, and D.E. Bambauer Reasons why few patients with acute stroke receive tissue plasminogen activator Arch Neurol 63 2006 661 664
10. G. Hademenos Metro Stroke Task Force: first-year experience Stroke 30 1999 2512
11. A.C. Flint, S.P. Cullen, and B.S. Faigeles Predicting long-term outcome after endovascular stroke treatment: the Totaled Health Risks in Vascular Events score AJNR Am J Neuroradiol 31 2010 1192 1196
12. H. Kamel, N. Patel, and V.A. Rao The Totaled Health Risks in Vascular Events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial J Stroke Cerebrovasc Dis 22 2013 1111 1116
13. H. Hallevi, A.D. Barreto, and D.S. Liebeskind Identifying patients at high risk for poor outcome after intra-arterial therapy for acute ischemic stroke Stroke 40 2009 1780 1785
14. A. Sarraj, K. Albright, and A.D. Barreto Optimizing prediction scores for poor outcome after intra-arterial therapy in anterior circulation acute ischemic stroke Stroke 44 2013 3324 3330
15. D. Strbian, S. Engelter, and P. Michel Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score Ann Neurol 71 2012 634 641
16. V.J. Howard, D.O. Kleindorfer, and S.E. Judd Disparities in stroke incidence contributing to disparities in stroke mortality Ann Neurol 69 2011 619 627
17. M.S. Pessin, G.J. Del Zoppo, and C.J. Estol Thrombolytic agents in the treatment of stroke Clin Neuropharmacol 13 1990 271 289
18. R. Bender, and S. Lange Adjusting for multiple testing-when and how? J Clin Epidemiol 54 2001 343 349
19. A.A. Ishkanian, M.E. McCullough-Hicks, and G. Appelboom Improving patient selection for endovascular treatment of acute cerebral ischemia: a review of the literature and an external validation of the Houston IAT and THRIVE predictive scoring systems Neurosurg Focus 30 2011 E7
20. L. Fjetland, S. Roy, and K.D. Kurz Neurointerventional treatment in acute stroke. Whom to treat? (Endovascular treatment for acute stroke: utility of THRIVE score and HIAT score for patient selection) Cardiovasc Intervent Radiol 36 2013 1241 1246
21. A.C. Flint, H. Kamel, and V.A. Rao Validation of the Totaled Heath Risks In Vascular Events (THRIVE) score for outcome prediction in endovascular stroke treatment Int J Stroke 9 2014 32 39
22. B. Ovbiagele, and J.L. Saver Day-90 acute ischemic stroke outcomes can be derived from early functional activity level Cerebrovasc Dis 29 2010 50 56